483 filings
Page 12 of 25
8-K
s685la7i5y4
19 Dec 11
Alexza Retains Lazard to Explore Strategic Options
12:00am
8-K
9qmfp
13 Dec 11
Other Events
12:00am
424B3
z73t82n
1 Dec 11
Prospectus supplement
12:00am
8-K
7vqzge jedf7lk
8 Nov 11
Alexza Presents Staccato® Loxapine Responder Analyses
12:00am
8-K
om57u5d
7 Nov 11
Alexza Reports 2011 Third Quarter Financial Results
12:00am
8-K
znwbn3hotjimy2 swnhk
4 Nov 11
Departure of Directors or Certain Officers
12:00am
8-K
z4qt0q0gzm946qqy6onx
27 Oct 11
Alexza Pharmaceuticals Announces Submission of European Marketing
12:00am
8-K
43ule4s
24 Oct 11
NDA Seeks Marketing Approval for ADASUVE for the Acute Treatment of Agitation
12:00am
8-K
2xm ukzqtims9
7 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
rzmbwwly2 r9
19 Aug 11
Application Seeks Marketing Approval for ADASUVE for the Rapid Treatment of Agitation in Adults with Schizophrenia or Bipolar Disorder
12:00am
S-8
r6dhos9qvv12d1y8n
9 Aug 11
Registration of securities for employees
12:00am
8-K
lem2ken1iy 5h6s
8 Aug 11
Alexza Reports 2011 Second Quarter Financial Results and Provides Business Update
12:00am
8-K
9z0ol6t vguyrgwp16tu
5 Aug 11
Alexza Announces Resubmission of AZ-004 (Staccato®Loxapine) NDA
12:00am
8-K
lvfdvmxs
2 Aug 11
Departure of Directors or Certain Officers
12:00am
8-K
y9vduo
26 Jul 11
Other Events
12:00am
DEFA14A
d9b73sf qleo
17 Jun 11
Additional proxy soliciting materials
12:00am